Immuno Cure is a biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody Immune Blocking technology platforms; with 2 vaccines in first-in-human clinical trials.
Location: China, Hong Kong, Sha Tin District
Investors 1
| Date | Name | Website |
| 21.08.2023 | Gobi Partn... | gobi.vc |
Mentions in press and media 14
| Date | Title | Description |
| 06.10.2025 | Immuno Cure wins Grand Prize at the National GBA Entrepreneurship Competition | “a prominent recognition attracting RMB 60M investment EOI” HONG KONG SAR – Media OutReach Newswire – 6 October 2025 – Immuno Cure BioTech (“Immuno Cure“) is delighted to announce victory at the National Final of the 1st GBA Entrepreneurshi... |
| 30.07.2025 | Shenzhen and Hong Kong Join Hands to Promote the Development of the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone | “Driving the Globalization of Clinical Trials in the Guangdong-Hong Kong-Macao Greater Bay Area, Implementing the First Key Cross-Border Multi-Center Clinical Trial Project” HONG KONG SAR – Media OutReach Newswire – 30 July 2025 – The Great... |
| 19.06.2025 | Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans | HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration with PharmaJet® to evaluate the ... |
| 13.11.2024 | FinTech and Biotech: A Tale of Innovation and Hope | In the bustling corridors of innovation, two stories emerge from Asia, each a beacon of progress in its field. On one side, we have On-us, a FinTech player redefining digital incentives. On the other, Immuno Cure Biotech, a pioneer in the f... |
| 12.11.2024 | Immuno Cure Biotech Presents Promising Results on Phase I Clinical Trial of a Therapeutic HIV DNA Vaccine | Encouraging findings with immunotherapy aiming at ART-free virological control A significant step towards functional cure of HIV infection HONG KONG SAR – Media OutReach Newswire – 12 November 2024 – Immuno Cure BioTech (“Immuno Cure“), a c... |
| 17.07.2024 | HKU AIDS Institute & Immuno Cure’s Collaborative Therapeutic HIV Vaccine Research Project secured HK$66.7m TRS funding from Research Grant Council | Research Funding for Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions HONG KONG SAR – Media OutReach Newswire – 18 July 2024 – Immuno Cure BioTech (“Immuno Cure“) is pleased to announce today that a collaborative researc... |
| 03.06.2024 | Immuno Cure’s Anti-Δ42PD1 Antibody Project Awarded HKSAR Government’s RAISe+ Scheme Funding | HONG KONG SAR – Media OutReach Newswire – 3 June 2024 – Immuno Cure BioTech (“Immuno Cure“) is delighted to announce that our pipeline product “Anti-Δ42PD1 Antibody against hepatocellular carcinoma (HCC)”, sublicensed to Orimmune BioTech Li... |
| 04.08.2023 | Gobi Partners’ strategic health tech investments signal growth opportunities in Asia | To solidify its position in the health tech sector, pan-Asian venture capital firm Gobi Partners has announced simultaneous investments in two key regions: China’s Greater Bay Area and Southeast Asia. With a total investment of USD 11.8 mil... |
| 27.07.2023 | Immuno Cure Completed US$12M First Close of Series A Financing, led by AEF GBA Fund managed by Gobi Partners GBA | Advancing DNA vaccines & Immunotherapies for HIV, Cancers & Infectious Diseases HONG KONG SAR – Media OutReach – 27 July 2023 – Immuno Cure BioTech (“Immuno Cure“) is pleased to announce today that it has closed the US$12 million tr... |
| 26.07.2023 | HK biotech firm Immuno Cure gears up for IPO with $12m funding | InvestmentsNewsStartups Lokesh Choudhary · 27 Jul 2023 · 2 min readHK biotech firm Immuno Cure gears up for IPO with $12m funding Photo credit: Shutterstock Immuno Cure has raised US$12 million as part of its US$27 million series A round. T... |
Show more